Genovese_Kremer_Mar2017

More documents

Recommendations

Info

Results – Baseline Demographics and Disease Activity (Study 2) Patient characteristic Placebo n=56 3 mg BID n=55 6 mg BID n=55 ABT-494 12 mg BID n=55 18 mg BID n=55 Age, mean (SD), years 58 (12) 57 (13) 56 (12) 59 (11) 57 (12) Female, n (%) 48 (86) 43 (78) 43 (78) 45 (82) 42 (76) RA duration, mean (SD), years Only 1 prior anti-TNF, n (%) Prior non-anti-TNF agent, n (%) 12.1 (9.0) 11.8 (9.4) 12.3 (10.6) 12.2 (10.2) 10.9 (7.7) 42 (76) 39 (71) 38 (70) 38 (72) 38 (69) 9 (16) 10 (18) 14 (26) 14 (26) 7 (13) HAQ-DI score, mean (SD) 1.6 (0.7) 1.5 (0.7) 1.6 (0.7) 1.6 (0.6) 1.5 (0.6) DAS28(CRP), mean (SD) 5.8 (0.9) 5.7 (0.9) 5.9 (0.9) 5.7 (0.9) 5.8 (1.0) CDAI score, mean (SD) 41 (12) 40 (13) 42 (12) 40 (12) 41 (14) hsCRP >ULN*, n (%) 28 (50) 35 (64) 34 (62) 33 (60) 35 (64) hsCRP, high-sensitivity C-reactive peptide; ULN, upper limit of normal (ULN=5 mg/L). <strong>Kremer</strong> JM, et al. Arthritis Rheum 2016;68:2867–77.
Results – Primary Endpoint MTX inadequate responders Placebo ABT-494 3 mg ABT-494 6 mg ABT-494 12 mg ABT-494 18 mg ABT-494 24 mg ACR20 rate (%) 46 62 68* 80* 64 76* *P
Page 1 and 2: Phase 2b Studies of ABT-494, a Sele
Page 3 and 4: Background and Objectives • ABT-4
Page 5 and 6: Methods - Study Design • These we
Page 7: Results - Baseline Demographics and
Page 11 and 12: Response rate (%) Response rate (%)
Page 13 and 14: Results - Safety Data Through Week
Page 15: Conclusions • Selective JAK-1 inh

Genovese_Kremer_Mar2017

Create successful ePaper yourself

Delete template?

Save as template?